Research
Rates of hemorrhage during warfarin therapy for atrial fibrillation
Tara Gomes, Muhammad M. Mamdani, Anne M. Holbrook, J. Michael Paterson, Chelsea Hellings and David N. Juurlink
CMAJ February 05, 2013 185 (2) E121-E127; DOI: https://doi.org/10.1503/cmaj.121218
Tara Gomes
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
MHScMuhammad M. Mamdani
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
PharmD MPHAnne M. Holbrook
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
MD PharmDJ. Michael Paterson
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
MScChelsea Hellings
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
MScDavid N. Juurlink
The Leslie Dan Faculty of Pharmacy (Gomes, Mamdani) and the Department of Health Policy, Management, and Evaluation (Juurlink, Mamdani, Paterson), University of Toronto; the Institute for Clinical Evaluative Sciences (Juurlink, Paterson, Hellings, Mamdani); the Sunnybrook Research Institute (Juurlink); and the Keenan Research Centre of the Li Ka Shing Knowledge Institute (Mamdani), St. Michael’s Hospital, Toronto, Ont.; the Department of Family Medicine (Paterson) and Division of Clinical Pharmacology & Therapeutics (Holbrook), McMaster University; and the Centre for Evaluation of Medicines (Holbrook, Paterson), St. Joseph’s Healthcare, Hamilton, Ont.
MD PhDData supplements
Related Articles
- (2013). Highlights. CMAJ, 185(2), 105. Accessed May 06, 2024. Retrieved from http://www.cmaj.ca/content/185/2/105.
In this issue
Article tools
Respond to this article
Rates of hemorrhage during warfarin therapy for atrial fibrillation
Tara Gomes, Muhammad M. Mamdani, Anne M. Holbrook, J. Michael Paterson, Chelsea Hellings, David N. Juurlink
CMAJ Feb 2013, 185 (2) E121-E127; DOI: 10.1503/cmaj.121218
Jump to section
Related Articles
Cited By...
- A genetic risk score improves risk stratification for anticoagulation-related intracerebral hemorrhage
- Adverse event rates associated with oral anticoagulant treatment early versus later after hospital discharge in older adults: a retrospective population-based cohort study
- Cardioembolic stroke: everything has changed
- Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
- Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF
- Association of Atrial Fibrillation and Oral Anticoagulant Use With Perioperative Outcomes After Major Noncardiac Surgery
- Clinical Application of Prothrombin Complex Concentrate in Blood Management in Patients
- Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation
- Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective--2016 Update
- Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke
- Plasma versus prothrombin complex concentrate for warfarin-associated major bleeding: a systematic review
- Adherence to oral anticoagulants in patients with atrial fibrillation--a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol
- Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation
- The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study
- Evaluation of an initiation protocol of 4 mg of warfarin for atrial fibrillation in the outpatient setting
- Use of blood products in patients with anticoagulant-related major bleeding: An analysis of inhospital outcomes
- Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention: A Contemporary Review
- Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
- Warfarin and absolute risk of hemorrhagic stroke